Awakening the Future: How Emerging Narcolepsy Type 1 Therapies Are Redefining Care and Expectations

In this episode of Unscripted – The AMCP Podcast, guest host Steve Kheloussi, PharmD, MBA, FAMCP, principal consultant at Kheloussi Consulting, speaks with Amy Lugo, PharmD, BCPS, BC-ADM, FAPhA, FAMCP, founder and CEO of LoneStar Health Solutions, about the evolving treatment landscape for narcolepsy. The discussion explores the burden of delayed diagnosis, the real-world impact of excessive daytime sleepiness and cataplexy, and how treatment may shift from symptom management toward addressing the underlying disease process. Steve and Amy also examine formulary considerations, patient-reported outcomes, utilization management challenges, and how managed care organizations can balance access, value, and patient-centered care as new therapies enter the market. 

This activity is supported by an independent medical education grant from Takeda Pharmaceuticals U.S.A., Inc. AMCP offers CPE for this podcast through June 30, 2027. Claim credit here.

Unscripted offers valuable updates for listeners and connects sponsors with health care professionals, payers, policymakers, regulators, and industry leaders. Sponsors benefit from a platform that connects them with a wide network of health care professionals, payers, and industry leaders. View podcast partner and advertising options, and view other Corporate Opportunities. 

View all podcasts: AMCP.org/podcast